Latest News and Press Releases

NEW HAVEN, Conn., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Modifi Biosciences, Inc. (“Modifi Biosciences”), a leader in the development of direct DNA modification enabled cancer therapeutics, today...

FLAG Therapeutics Announces Encouraging Preclinical Data from Studies of FLAG-003 for the Treatment of Diffuse Intrinsic Pontine Glioma (DIPG)

MB-101 was well-tolerated and 50% of patients achieved stable disease or better with two partial responses and two complete responses lasting 7.5 and 66+ months, respectively ~70% improvement in...

New York, USA, May 17, 2023 (GLOBE NEWSWIRE) -- Propulsion of Glioma Clinical Trial Pipeline as Novel and Extensive 220+ Therapies Likely to Enter in the Treatment Domain | DelveInsight The glioma...

RALEIGH, N.C., Jan. 31, 2023 (GLOBE NEWSWIRE) -- FLAG Therapeutics, Inc., announced today that FLAG-003, an investigational small molecule therapy for the treatment of Diffuse Intrinsic Pontine...

TORONTO, Oct. 26, 2022 (GLOBE NEWSWIRE) -- For Canadians diagnosed with brain cancer, where they live determines how much access they have to treatment, according to new research by the charity...

TORONTO, May 01, 2022 (GLOBE NEWSWIRE) -- Today marks the first day of Brain Cancer Awareness month. On this day Brain Cancer Canada grants $100,000 to the St. Michael's Hospital program to acquire...

TORONTO, Nov. 30, 2021 (GLOBE NEWSWIRE) -- A pioneering approach led by Prof. Patrick Gunning at the University of Toronto, leveraging advanced medicinal chemistry to help develop potential...

TORONTO, Oct. 24, 2021 (GLOBE NEWSWIRE) -- Brain Cancer Canada has issued a $100,000 grant to Canadian research exploring new frontiers of brain cancer treatment. Drs. Cynthia Hawkins and Roman...

Lexington, KY, April 15, 2021 (GLOBE NEWSWIRE) -- NX Development Corp. (NXDC), a life-sciences company wholly owned by photonamic GmbH & Co. KG., today announced that Tracy Jerome “T.J.” ...